Adverse drug interactions and reactions in dermatology: Current issues of clinical relevance

Dermatologic Clinics

Volumn 23, Issue 2, 2005, Pages 335-342

  Wong, Gavin A E ^a   Shear, Neil H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMITRIPTYLINE; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CETUXIMAB; CIPROFLOXACIN; CYCLOSPORIN; ENOXACIN; ERLOTINIB; ETIDRONIC ACID; FERROUS SULFATE; FEXOFENADINE; GEFITINIB; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NORFLOXACIN; OFLOXACIN; OMEPRAZOLE; PAMIDRONIC ACID; PHENPROCOUMON; POLYCARBOPHIL CALCIUM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACNE; CLINICAL PRACTICE; CLINICAL TRIAL; COMEDO; CONFUSION; CORRELATION ANALYSIS; CROSS REACTION; DERMATOLOGY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRY SKIN; DYSURIA; ENZYME INDUCTION; ERYTHEMA; FLUSHING; FOLLICULITIS; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HEADACHE; HERBAL MEDICINE; HISTOPATHOLOGY; HUMAN; HYPERICUM PERFORATUM; INFLAMMATION; LICHENOID ERUPTION; MILK; MOUTH ULCER; MYALGIA; NAIL DISEASE; NONHUMAN; PAPULE; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; PUSTULE; RESTLESSNESS; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; SKIN MANIFESTATION; SKIN TOXICITY; SULFA ALLERGY; TREMOR; VAGINAL DRYNESS;

EID: 17044422053     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.08.001     Document Type: Review

References (71)

1. L.E. Shapiro, S.R. Knowles, and N.H. Shear Drug interactions of clinical significance for the dermatologist Am J Clin Dermatol 4 9 2003 623 639
2. N. Aria, and L. Kauffman Important drug interactions and reactions in dermatology Dermatol Clin 21 2003 207 215
3. T.C. Roos, and H.F. Merk Important drug interactions in dermatology Drugs 59 2 2000 181 192
4. M. Lebwohl, J.M. Gelfand, and M.H. Tan Clinically significant therapeutic interactions for the practicing dermatologist Adv Dermatol 14 1999 1 26
5. D. Sadowski Drug interactions with antacids Drug Saf 11 1994 395 407
6. D.A. Carrasco, M. Vander Straten, and S.K. Tyring A review of antibiotics in dermatology J Cutan Med Surg 6 2 2002 128 150
7. P.J. Neuvonen Interactions with the absorption of tetracyclines Drugs 11 1976 45 54
8. J.J. Leyden Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron J Am Acad Dermatol 12 1985 308 312
9. D. Sable, and G.J. Murukawa Quinolones in dermatology Clin Dermatol 21 2003 56 63
10. B.M. Lomaestro, and G.R. Bailie Absorption interactions with fluoroquinolones Drug Saf 12 1995 314 333
11. E.P. Boling Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis Clin Ther 26 2004 1 14
12. J.H. Lin Bisphosphonates: a review of their pharmacokinetic properties Bone 18 1996 75 85
13. V. Liu, and B.T. Mackool Mycophenolate in dermatology J Dermatol Treat 14 2003 203 210
14. R. Kato, K. Ooi, M. Ikura-Morii, Y. Tsuchishita, H. Hashimoto, and H. Yoshimura Impairment of mycophenolate mofetil absorption by calcium polycarbophil J Clin Pharm 42 2002 1275 1280
15. M. Morii, K. Ueno, A. Ogawa, R. Kato, H. Yoshimuro, and K. Wada Impairment of mycophenolate mofetil absorption by iron ion Clin Pharmacol Ther 68 2000 613 616
16. M. Pirmohamed Herbal medicines Postgrad Med J 79 2003 489
17. P.A.G.M. De Smet Herbal remedies N Engl J Med 347 2002 2046 2056
18. E.M. Williamson Drug interactions between herbal and prescription medicines Drug Saf 26 2003 1075 1092
19. A. Fugh-Berman, and E. Ernst Herb-drug interactions: review and assessment of report reliability Br J Clin Pharmacol 52 2001 587 595
20. A.A. Izzo, and E. Ernst Interactions between herbal medicines and prescribed drugs Drugs 61 2001 2163 2175
21. A. Fugh-Berman Herb-drug interactions Lancet 355 2000 134 138
22. N.C. Brazier, and M.A.H. Levine Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals Am J Ther 10 2003 163 169
23. L. Henderson, Q.Y. Yue, C. Bergquist, B. Gerden, and P. Arlett St. John's wort (hypericum perforatum): drug interactions and clinical outcomes Br J Clin Pharmacol 54 2002 349 356
24. Z. Wang, C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 2001 317 326
25. J.S. Markowitz, J.L. Donovan, C.L. DeVane, R.M. Taylor, Y. Ruan, and J.S. Wang Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme JAMA 290 2003 1500 1504
26. S. Zhou, G. Yihuai, W. Jiang, M. Huang, A. Xu, and J.W. Paxton Interactions of herbs with cytochrome P450 Drug Metab Rev 35 2003 35 98
27. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, and T.M. Willson St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci U S A 97 2000 7500 7502
28. D. Durr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, and P.J. Meier St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 2000 598 604
29. M. Hennessy, D. Kelleher, J.P. Spiers, M. Barry, P. Kavanagh, and D. Back St. John's wort increases expression of P-glycoprotein: implications for drug interactions Br J Clin Pharmacol 53 2002 75 82
30. A. Johne, J. Schmider, J. Brockmoller, A.M. Stadelmann, E. Stormer, and S. Bauer Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum) J Clin Psychopharmacol 22 2002 46 54
31. E. Ernst St. John's wort supplements endanger the success of organ transplantation Arch Surg 137 2002 316 319
32. A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 1999 338 345
33. Z. Wang, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall Effect of St. John's wort on the pharmacokinetics of fexofenadine Clin Pharmacol Ther 71 2002 414 420
34. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, and J. Falloon Indinavir concentrations and St. John's wort Lancet 355 9203 2000 547 548
35. M.M.R. de Maat, R.M.W. Hoetelmans, R.A.A. Mathot, E.C.M. van Gorp, P.L. Meenhorst, and J.W. Mulder Drug interaction between St. John's wort and nevirapine AIDS 15 2001 420 421
36. L.S. Wang, G. Zhou, B. Zhu, J. Wu, J.G. Wang, and A.M. Abd El-aty St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 2004 191 197
37. A. Maurer, A. Johne, S. Bauer, F. Brockmoller, F. Donath, and I. Roots Interaction of St. John's wort extract with phenprocoumon Eur J Clin Pharmacol 55 1999 A22
38. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, and K. Harada Different effects of St. John's Wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524
39. I. Mai, E. Stormer, S. Bauer, H. Kruger, K. Budde, and I. Roots Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients Nephrol Dial Transplant 18 2003 819 822
40. A. Nebel, B.J. Schneider, R.K. Baker, and D.J. Kroll Potential metabolic interaction between St. John's wort and theophylline Ann Pharmacother 33 1999 502
41. Q.Y. Yue, C. Bergquist, and B. Gerden Safety of St. John's wort (Hypericum perforatum) Lancet 355 2000 576 577
42. U.I. Schwarz, B. Buschel, and W. Kirch Unwanted pregnancy on self-medication with St. John's wort despite hormonal contraception Br J Clin Pharmacol 55 2003 112 113
43. S.D. Hall, Z. Wang, S.M. Huang, M.A. Hamman, N. Vasavada, and A.Q. Adigun The interaction between St. John's wort and an oral contraceptive Clin Pharmacol Ther 74 2003 525 535
44. A. Pfrunder, M. Schiesser, S. Gerber, M. Haschke, J. Bitzer, and J. Drewe Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial Br J Clin Pharmacol 56 2003 683 690
45. S. Knowles, L. Shapiro, and N.H. Shear Should celecoxib be contraindicated in patients who are allergic to sulfonamides. Revisiting the meaning of "sulfa" allergy Drug Saf 24 2001 239 247
46. A.E. Cribb, B.L. Lee, L.A. Trepanier, and S.P. Spielberg Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis Adverse Drug React Toxicol Rev 15 1996 9 50
47. D.J. Naisbitt, S.J. Hough, H.J. Gill, M. Pirmohamed, N. Kitteringham, and B.K. Park Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity Br J Pharmacol 126 1999 1393 1407
48. D.G. Harle, B.A. Baldo, and J.V. Wells Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole Mol Immunol 25 1988 1347 1354
49. B.E. Wiholm Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Drug Saf 25 2002 297 300
50. B.L. Strom, R. Schinnar, A.J. Apter, D.J. Margolis, E. Lautenbach, and S. Hennessy Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics N Engl J Med 349 2003 1628 1635
51. A.S. Saxon, and E. Macy Cross-reactivity and sulfonamide antibiotics N Engl J Med 350 3 2004 302 303
52. W.J. Pichler Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept Curr Opin Allergy Clin Immunol 2 2002 301 305
53. J.P.H. Depta, and W.J. Pichler Cross-reactivity with drugs at the T cell level Curr Opin Allergy Clin Immunol 3 2003 261 267
54. L.E. Shapiro, S.R. Knowles, E. Weber, M.G. Neuman, and N.H. Shear Safety of celecoxib in individuals allergic to sulfonamide. A pilot study Drug Saf 26 2003 187 195
55. S. Yano, K. Kondo, M. Yamaguchi, G. Richmond, M. Hutchison, and A. Wakeling Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Res 23 2003 3639 3650
56. L.B. Nanney, M. Magid, C.M. Stoscheck, and L.E. King Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages J Invest Dermatol 83 1984 385 393
57. M. Jost, C. Kari, and U. Rodeck The EGF receptor: an essential regulator of multiple epidermal functions Eur J Dermatol 10 2000 505 510
58. C.A. Ritter, and C.L. Arteaga The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors Semin Oncol 30 Suppl 1 2003 3 11
59. C.Y. Liu, and S. Seen Gefitinib therapy for advanced non-small cell lung cancer Ann Pharmacother 37 2003 1644 1653
60. P. Bonomi Clinical studies with non-iressa EGFR tyrosine kinase inhibitors Lung Cancer 41 Suppl 1 2003 S43 S48
61. N.A. Reynolds, and A.J. Wagstaff Cetuximab in the treatment of metastatic colorectal cancer Drugs 64 2004 109 118
62. A. Lage, T. Crombet, and G. Gonzalez Targeting epidermal growth factor receptor signaling: early results and future trends in oncology Ann Med 35 2003 327 336
63. K.J. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, and A.C. Halpern Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 144 2001 1169 1176
64. A. Kimyai-Asadi, and M.H. Jih Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors Arch Dermatol 138 2002 129 131
65. R. van Doorn, G. Kirtschig, E. Scheffer, T.J. Stoof, and G. Giaccone Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Br J Dermatol 147 2002 598 601
66. R.S. Herbst, P.M. LoRusso, M. Purdom, and D. Ward Dermatologic side effects associated with gefitinib therapy: clinical experience and management Clin Lung Cancer 4 2003 366 369
67. M.W. Lee, C.W. Seo, S.W. Kim, H.J. Yang, H.W. Lee, and J.H. Choi Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor Acta Derm Venereol 84 2004 23 26
68. G.A. Wong, S. Nigen, S. Walsh, and N.H. Shear Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 [abstract] J Am Acad Dermatol 50 3 Suppl 2004 39
69. N. van Zandwijk Tolerability of gefitinib in patients receiving treatment in everyday clinical practice Br J Cancer 89 Suppl 2 2003 S9 S14
70. J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J.M. Mascaro, and R. Herbst Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 2001 110 124
71. L.A. Hansen, N. Alexander, M.E. Hogan, J.P. Sundberg, A. Dlugosz, and D.W. Threadgill Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development Am J Pathol 150 1997 1959 1975